Goyal Jay, Iyer Shruthi, Palande Chinmayee, Brahmankar Ujwala, John Janice, Patil Kshitija
Department of Oral Surgery, Jawahar Medical Foundation's ACPM Dental College, Dhule, Maharashtra 424001, India.
Department of Oral Medicine, Jawahar Medical Foundation's ACPM Dental College, Dhule, Maharashtra 424001, India.
Med Int (Lond). 2024 Feb 26;4(2):19. doi: 10.3892/mi.2024.143. eCollection 2024 Mar-Apr.
The prevalent symptoms of oral submucous fibrosis (OSMF) are a burning sensation and trismus. The aim of the present study was to compare the efficacy of placentrex, hyaluronidase and dexamethasone, and their combination in the treatment of OSMF. For this purpose, 160 patients with OSMF were divided into four groups (each with 40 patients at a 1:1:1:1 allocation ratio). The patients in group 1 (control) received only oral supplements, along with regular mouth-opening exercises; patients in group 2 received an injection of placental extract; patients in group 3 were injected with hyaluronidase and dexamethasone; and patients in group 4 received a combination of injections from groups 2 and 3. The injections were administered once weekly for 12 weeks and patients were followed-up for 12 months. The data of the patients (mouth opening ability and a burning sensation) were analyzed using ANOVA and the Kruskal-Wallis test. The maximum increase in mouth opening (7.30±0.80 mm) was noted in group 4, and the lease increase was observed in the control group (0.37±0.16 mm), from baseline levels to the end of the 12th week. The maximum relapse in mouth opening of 1.62±0.45 mm was noted in group 2, and a minimum relapse of 0.20±0.08 mm was noted in group 4. On the whole, the present study demonstrates that the intralesional injection of a combination of the three drugs (placentrex, hyaluronidase and dexamethasone) in addition to the use of oral supplements and mouth opening exercises has a high level of efficacy in improving trismus and burning sensation in patients with OSMF.
口腔黏膜下纤维化(OSMF)的常见症状是烧灼感和张口受限。本研究的目的是比较胎盘组织液、透明质酸酶和地塞米松及其联合用药治疗OSMF的疗效。为此,将160例OSMF患者分为四组(每组40例,分配比例为1:1:1:1)。第1组(对照组)患者仅接受口服补充剂,并进行常规张口训练;第2组患者注射胎盘提取物;第3组患者注射透明质酸酶和地塞米松;第4组患者接受第2组和第3组注射药物的联合治疗。每周注射一次,共12周,并对患者进行12个月的随访。使用方差分析和Kruskal-Wallis检验分析患者的数据(张口能力和烧灼感)。从基线水平到第12周结束时,第4组的张口最大增加量为(7.30±0.80 mm),对照组的增加量最小(0.37±0.16 mm)。第2组的张口最大复发量为1.62±0.45 mm,第4组的最小复发量为0.20±0.08 mm。总体而言,本研究表明,除了使用口服补充剂和张口训练外,病灶内注射三种药物(胎盘组织液、透明质酸酶和地塞米松)的组合对改善OSMF患者的张口受限和烧灼感具有很高的疗效。